Changes in the Treatment Landscape of Early-Stage Non–Small Cell Lung Cancer

Narjust Florez, MD

January 04, 2024

Dr Narjust Florez explores the transformative shifts in the treatment landscape for early-stage non–small cell lung cancer over the years, particularly emphasizing the significant changes observed since 2020.

The pivotal ADAURA trial marked a turning point, introducing adjuvant targeted therapy and influencing the treatment approach for early-stage non–small cell lung cancer. In addition, she touches on other recent advances, including biomarker testing and immunotherapy. Dr Florez expresses her optimism for the future in terms of an increase in lung cancer screening, expanding options for patients, and improved overall survival rates while also highlighting the need to align with the rapid pace of scientific advancements.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Changes in the Treatment Landscape of Early-Stage Non–Small Cell Lung Cancer - Medscape - Jan 04, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.